Won‐Il Jeong, Ogyi Park, Yang‐Gun Suh, Jin‐Seok Byun, So‐Young Park, Earl Choi, Ja‐Kyung Kim, Hyojin Ko, Hua Wang, Andrew M. Miller, Bin Gao – 12 January 2011 – Activation of innate immunity (natural killer [NK] cell/interferon‐γ [IFN‐γ]) has been shown to play an important role in antiviral and antitumor defenses as well as antifibrogenesis. However, little is known about the regulation of innate immunity during chronic liver injury.

Liang Shen – 12 January 2011

Anna Alisi, Melania Manco, Marco Pezzullo, Valerio Nobili – 12 January 2011

David E. J. Jones, George Mells – 12 January 2011

Gail V. Matthews, Gregory J. Dore – 12 January 2011

Liang Bai, Yuzhi Jia, Navin Viswakarma, Jiansheng Huang, Aurore Vluggens, Nathan E. Wolins, Nadereh Jafari, M. Sambasiva Rao, Jayme Borensztajn, Gongshe Yang, Janardan K. Reddy – 12 January 2011 – Peroxisome proliferator‐activated receptor‐γ (PPARγ), a nuclear receptor, when overexpressed in liver stimulates the induction of adipocyte‐specific and lipogenesis‐related genes and causes hepatic steatosis.

Jasmohan S. Bajaj, Oliviero Riggio – 12 January 2011

Ingrid Imhof, Peter Simmonds – 11 January 2011 – Protease inhibitors (PIs) have proven to be effective adjuncts to interferon/ribavirin treatment of hepatitis C virus (HCV) infections. Little clinical or in vitro data exists, however, on their effectiveness for nontype 1 genotypes that predominate in Europe, the Middle East, Africa, and most of Asia. NS3 protease and NS4A genes from genotypes 1‐6 were inserted into the JFH clone to generate replication‐competent intergenotype chimeras. Susceptibility to PIs was determined by replication and infectivity assays.

Andrew X. Zhu, Aram F. Hezel – 11 January 2011 – Biliary tract cancers (BTCs), which encompass intra‐ and extrahepatic cholangiocarcinomas as well as gallbladder carcinomas, are a genetically diverse collection of cancers. Most patients with BTC will present with unresectable or metastatic disease. Although the standard systemic chemotherapy approaches are emerging, the prognosis remains poor. Development of molecularly targeted therapies in advanced BTC remains challenging.

Philip Meuleman, Jens Bukh, Lieven Verhoye, Ali Farhoudi, Thomas Vanwolleghem, Richard Y. Wang, Isabelle Desombere, Harvey Alter, Robert H. Purcell, Geert Leroux‐Roels – 11 January 2011 – Control of hepatitis C virus (HCV) infection remains a huge challenge of global medical importance. Using a variety of in vitro approaches, neutralizing antibodies (nAbs) have been identified in patients with acute and chronic hepatitis C. The exact role these nAbs play in the resolution of acute HCV infection still remains elusive.